aspartic acid has been researched along with Atrophy in 102 studies
Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.
aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent
L-aspartic acid : The L-enantiomer of aspartic acid.
Atrophy: Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We observed mild cerebral and cerebellar atrophy and infarct at bilateral posterior putamen and insular cortex localization on conventional images and elevated choline/creatine ratios and abnormal peak at 3." | 7.74 | Neuroimaging findings in hyperargininemia. ( Akinci, A; Alkan, A; Firat, AK; Güngör, S; Tabel, Y, 2008) |
| "The authors compared temporal profiles of N-acetylaspartate (NAA) and the NAA/total creatine ratio with neuronal and astrocytic densities and with tissue atrophy in the hippocampal CA1 sector of gerbils after 5-minute bilateral forebrain ischemia and subsequent reperfusion for up to 6 months." | 7.72 | N-acetylaspartate to total creatine ratio in the hippocampal CA1 sector after transient cerebral ischemia in gerbils: influence of neuronal elements, reactive gliosis, and tissue atrophy. ( Konaka, K; Li, JY; Matsumoto, M; Sakoda, S; Ueda, H; Yanagihara, T, 2003) |
| "The early-weaned pig develops intestinal atrophy and provides a readily accessible animal model for determining the role of dietary supplementation of glutamine (Gln, a major fuel for enterocytes) in preventing intestinal damage." | 7.69 | Dietary glutamine supplementation prevents jejunal atrophy in weaned pigs. ( Knabe, DA; Meier, SA; Wu, G, 1996) |
| "Excessive excretion of N-acetylaspartic acid in urine is reported in a 6-yr-old child with extensive and progressive cerebral atrophy." | 7.67 | N-acetylaspartic aciduria in a child with a progressive cerebral atrophy. ( Børsting, S; Guldal, G; Jellum, E; Kvittingen, EA; Skalpe, IO; Stokke, O, 1986) |
| " Neuroimaging measures were central (ventricular) cerebral atrophy, lesion volume, and ratios of N-acetyl aspartate (NAA) to both creatine and choline." | 5.10 | Cognitive performance and MR markers of cerebral injury in cognitively impaired MS patients. ( Christodoulou, C; Huang, W; Krupp, LB; Li, L; Li, X; Liang, Z; MacAllister, WS; Melville, P; Morgan, T; Peyster, R; Roche, P; Roque, C; Scherl, WF; Tudorica, LA, 2003) |
| " We observed mild cerebral and cerebellar atrophy and infarct at bilateral posterior putamen and insular cortex localization on conventional images and elevated choline/creatine ratios and abnormal peak at 3." | 3.74 | Neuroimaging findings in hyperargininemia. ( Akinci, A; Alkan, A; Firat, AK; Güngör, S; Tabel, Y, 2008) |
| "Mesial temporal lobe epilepsy (mTLE) is characterized by hippocampal atrophy, decreased N-acetyl-aspartate, and a low N-acetyl-aspartate/total creatine ratio, often attributed to neuron loss and gliosis." | 3.72 | N-acetyl-aspartate, total creatine, and myo-inositol in the epileptogenic human hippocampus. ( Errante, LD; Kim, JH; Petroff, OA; Spencer, DD, 2003) |
| "The authors compared temporal profiles of N-acetylaspartate (NAA) and the NAA/total creatine ratio with neuronal and astrocytic densities and with tissue atrophy in the hippocampal CA1 sector of gerbils after 5-minute bilateral forebrain ischemia and subsequent reperfusion for up to 6 months." | 3.72 | N-acetylaspartate to total creatine ratio in the hippocampal CA1 sector after transient cerebral ischemia in gerbils: influence of neuronal elements, reactive gliosis, and tissue atrophy. ( Konaka, K; Li, JY; Matsumoto, M; Sakoda, S; Ueda, H; Yanagihara, T, 2003) |
| "To assess whether differences in cerebral atrophy and white matter lesions or in the presence of lactate and lipid signals can explain the observed differences in brain choline, creatine, and N-acetylaspartate levels between healthy elderly women and men." | 3.71 | Human brain chemical shift imaging at age 60 to 90: analysis of the causes of the observed sex differences in brain metabolites. ( Achten, E; Breteler, MM; De Groot, JC; De Leeuw, FE; Den Heijer, T; Heijboer, RJ; Hofman, A; Oudkerk, M; Sijens, PE, 2001) |
| " Thalamic and white matter metabolite concentrations (myo-inositol (mI), choline-containing compounds (Cho), total creatine (Cr) and N-acetylaspartate (NAA)) were estimated and corrected for atrophy (CSF) and gray and white matter contributions (GM, WM) by use of image-based voxel segmentation." | 3.71 | Reduced NAA in the thalamus and altered membrane and glial metabolism in schizophrenic patients detected by 1H-MRS and tissue segmentation. ( Auer, DP; Bronisch, T; Grabner, A; Heidenreich, JO; Wetter, TC; Wilke, M, 2001) |
| "The N-acetylaspartate-to-creatine/phosphocreatine ratio was smaller in those patients with significant cerebral atrophy (1." | 3.69 | Analysis of cerebral structural changes in systemic lupus erythematosus by proton MR spectroscopy. ( Griffey, RH; Hart, BL; Haseler, LJ; Matwiyoff, NA; Sibbitt, RR; Sibbitt, WL, 1994) |
| "The early-weaned pig develops intestinal atrophy and provides a readily accessible animal model for determining the role of dietary supplementation of glutamine (Gln, a major fuel for enterocytes) in preventing intestinal damage." | 3.69 | Dietary glutamine supplementation prevents jejunal atrophy in weaned pigs. ( Knabe, DA; Meier, SA; Wu, G, 1996) |
| "Excessive excretion of N-acetylaspartic acid in urine is reported in a 6-yr-old child with extensive and progressive cerebral atrophy." | 3.67 | N-acetylaspartic aciduria in a child with a progressive cerebral atrophy. ( Børsting, S; Guldal, G; Jellum, E; Kvittingen, EA; Skalpe, IO; Stokke, O, 1986) |
| "Posttraumatic stress disorder (PTSD) is a trauma and stressor-related disorder that results in complex somatic, cognitive, affective and behavioural effects, after exposure to traumatic event(s)." | 2.58 | Systematic review of in-vivo neuro magnetic resonance spectroscopy for the assessment of posttraumatic stress disorder. ( Mountford, C; Quadrelli, S; Ramadan, S, 2018) |
| "Background GM1 gangliosidosis is a lysosomal storage disorder caused by mutations in GLB1, encoding β-galactosidase." | 1.43 | MRI/MRS as a surrogate marker for clinical progression in GM1 gangliosidosis. ( Adams, D; Baker, EH; Golas, G; Johnston, J; Kwon, HJ; Latour, Y; Portner, C; Regier, DS; Thomas, S; Tifft, CJ; Vezina, G; Wiggs, E; Yang, S, 2016) |
| "Data from 21 patients with primary progressive multiple sclerosis within 6 years of disease onset, and 24 control subjects were analysed." | 1.42 | Evidence for early neurodegeneration in the cervical cord of patients with primary progressive multiple sclerosis. ( Abdel-Aziz, K; Altmann, DR; Ciccarelli, O; Day, BL; Peters, AL; Schneider, T; Solanky, BS; Thompson, AJ; Wheeler-Kingshott, CA; Yiannakas, MC, 2015) |
| "The precise pathogenic mechanisms of Huntington's disease (HD) are unknown but can be tested in vivo using proton magnetic resonance spectroscopy ((1)H MRS) to measure neurochemical changes." | 1.40 | Neurochemical correlates of caudate atrophy in Huntington's disease. ( Aylward, EH; Conley, KE; Laurino, MY; Padowski, JM; Richards, TL; Samii, A; Weaver, KE, 2014) |
| "Hypertension is associated with cognitive decline in elderly persons." | 1.36 | Posterior paralimbic and frontal metabolite impairments in asymptomatic hypertension with different treatment outcomes. ( Antequera, M; Antúnez, C; Campoy, G; Carrillo, A; Fuentes, LJ; García Santos, JM; García-Sevilla, J; Ortega, G; Torres del Río, S; Vidal, JB, 2010) |
| "Co-morbidities of PTSD, notably alcohol abuse, may have contributed to the inconsistency." | 1.35 | Abnormal N-acetylaspartate in hippocampus and anterior cingulate in posttraumatic stress disorder. ( Fox-Bosetti, S; Kornak, J; Lenoci, M; Marmar, CR; Neylan, TC; Samuelson, KW; Schuff, N; Studholme, C; Weiner, MW, 2008) |
| "Chronic alcohol abuse results in morphological, metabolic, and functional brain damage which may, to some extent, be reversible with early effects upon abstinence." | 1.34 | Manifestations of early brain recovery associated with abstinence from alcoholism. ( Bartsch, AJ; Bendszus, M; Biller, A; De Stefano, N; Homola, G; Jenkinson, M; Smith, SM; Solymosi, L; Weijers, HG; Wiesbeck, GA, 2007) |
| "Brain damage in Alzheimer's disease (AD) and mild cognitive impairment (MCI) is widespread with involvement of large portions of the neocortex and the subcortical white matter." | 1.33 | A whole brain MR spectroscopy study from patients with Alzheimer's disease and mild cognitive impairment. ( Benedetti, B; Bozzali, M; Comi, G; Falini, A; Filippi, M; Franceschi, M; Gambini, A; Magnani, G; Mossini, R; Pero, G; Scotti, G, 2005) |
| "PEHO syndrome is a rare symptom complex of severe progressive encephalopathy, edema, hypsarrhythmia, and optic atrophy." | 1.33 | Serial MR imaging, diffusion tensor imaging, and MR spectroscopic findings in a child with progressive encephalopathy, edema, hypsarrhythmia, and optic atrophy (PEHO) syndrome. ( Boltshauser, E; Huisman, TA; Klein, A; Straube, T; Werner, B, 2006) |
| "Canavan disease is a childhood leukodystrophy caused by mutations in the gene for human aspartoacylase ( ASPA), which leads to an abnormal accumulation of the substrate molecule N-acetyl-aspartate (NAA) in the brain." | 1.33 | Natural history of Canavan disease revealed by proton magnetic resonance spectroscopy (1H-MRS) and diffusion-weighted MRI. ( Assadi, M; Bilaniuk, L; Francis, J; Freese, A; Haselgrove, J; Hurh, P; Janson, CG; Leone, P; McPhee, SW; Shera, D; Wang, DJ, 2006) |
| "In these patients spasticity began in the legs and progressed slowly and steadily." | 1.32 | Primary lateral sclerosis: A heterogeneous disorder composed of different subtypes? ( Butman, JA; Floeter, MK; Pagan, F; Statland, J; Zhai, P, 2003) |
| "The progression of Wilson disease (WD), a disorder of copper metabolism, can be arrested by chelation therapy." | 1.32 | Clinical correlation of brain MRI and MRS abnormalities in patients with Wilson disease. ( Davie, CA; Lees, AJ; MacManus, D; Miller, DH; Miszkiel, KA; Page, RA; Schapira, AH; Walshe, JM, 2004) |
| "Eleven IDDM patients with no history of severe hypoglycemia (group A) were compared with 11 IDDM patients who had a history of five or more episodes of severe hypoglycemia (group B)." | 1.30 | Brain abnormalities demonstrated by magnetic resonance imaging in adult IDDM patients with and without a history of recurrent severe hypoglycemia. ( Best, JJ; Deary, IJ; Frier, BM; Perros, P; Sellar, RJ, 1997) |
| "Patients with AIDS had more signs of neurological dysfunction, poorer performance on a neuropsychological test battery, were more likely to have an abnormal EEG, and to have abnormalities on MRI." | 1.30 | Evidence of CNS impairment in HIV infection: clinical, neuropsychological, EEG, and MRI/MRS study. ( Carter, S; Fowler, CJ; Hall-Craggs, MA; Harrison, MJ; Kendall, BE; Lunn, S; Miller, R; Newman, SP; Paley, M; Sweeney, B; Wilkinson, I; Williams, I, 1998) |
| "Four grades of demyelination and three grades of cerebral atrophy were distinguished by magnetic resonance imaging criteria." | 1.28 | 1H and 31P magnetic resonance spectroscopy of the brain in degenerative cerebral disorders. ( den Hollander, JA; Luyten, PR; Nauta, JJ; Valk, J; van der Grond, J; van der Knaap, MS, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (6.86) | 18.7374 |
| 1990's | 19 (18.63) | 18.2507 |
| 2000's | 50 (49.02) | 29.6817 |
| 2010's | 21 (20.59) | 24.3611 |
| 2020's | 5 (4.90) | 2.80 |
| Authors | Studies |
|---|---|
| Piao, S | 1 |
| Bao, Y | 1 |
| Yang, L | 1 |
| Zhang, Y | 1 |
| Hu, B | 1 |
| Li, H | 1 |
| Geng, D | 1 |
| Li, Y | 1 |
| Chang, MC | 1 |
| Staklinski, SJ | 1 |
| Malut, VR | 1 |
| Pierre, GL | 1 |
| Kilberg, MS | 1 |
| Merritt, ME | 1 |
| Hull, VL | 1 |
| Wang, Y | 2 |
| Burns, T | 2 |
| Sternbach, S | 2 |
| Gong, S | 1 |
| McDonough, J | 2 |
| Guo, F | 2 |
| Borodinsky, LN | 1 |
| Pleasure, D | 2 |
| Blicher, JU | 1 |
| Eskildsen, SF | 1 |
| Stærmose, TG | 1 |
| Møller, AT | 1 |
| Figlewski, K | 1 |
| Near, J | 1 |
| Hull, V | 1 |
| Zhang, S | 2 |
| Kirov, II | 2 |
| Sollberger, M | 3 |
| Davitz, MS | 2 |
| Glodzik, L | 3 |
| Soher, BJ | 2 |
| Babb, JS | 7 |
| Monsch, AU | 3 |
| Gass, A | 3 |
| Gonen, O | 9 |
| Bodini, B | 1 |
| Branzoli, F | 1 |
| Poirion, E | 1 |
| García-Lorenzo, D | 1 |
| Didier, M | 1 |
| Maillart, E | 1 |
| Socha, J | 1 |
| Bera, G | 1 |
| Lubetzki, C | 1 |
| Ronen, I | 1 |
| Lehericy, S | 1 |
| Stankoff, B | 1 |
| Kuzniecky, R | 1 |
| Hetherington, HP | 1 |
| Pardoe, HR | 1 |
| Pan, JW | 1 |
| Crespo-Eguilaz, N | 1 |
| Dominguez, PD | 1 |
| Vaquero, M | 1 |
| Narbona, J | 1 |
| Quadrelli, S | 1 |
| Mountford, C | 1 |
| Ramadan, S | 1 |
| Polacek, H | 1 |
| Kantorova, E | 1 |
| Hnilicova, P | 1 |
| Grendar, M | 1 |
| Zelenak, K | 1 |
| Kurca, E | 1 |
| Wang, W | 1 |
| Sun, H | 1 |
| Su, X | 1 |
| Tan, Q | 1 |
| Xia, C | 1 |
| Li, L | 2 |
| Kemp, GJ | 1 |
| Yue, Q | 1 |
| Gong, Q | 1 |
| Padowski, JM | 1 |
| Weaver, KE | 1 |
| Richards, TL | 1 |
| Laurino, MY | 1 |
| Samii, A | 1 |
| Aylward, EH | 1 |
| Conley, KE | 1 |
| Llufriu, S | 1 |
| Kornak, J | 2 |
| Ratiney, H | 1 |
| Oh, J | 2 |
| Brenneman, D | 1 |
| Cree, BA | 1 |
| Sampat, M | 1 |
| Hauser, SL | 1 |
| Nelson, SJ | 2 |
| Pelletier, D | 2 |
| Abdel-Aziz, K | 1 |
| Schneider, T | 1 |
| Solanky, BS | 1 |
| Yiannakas, MC | 1 |
| Altmann, DR | 1 |
| Wheeler-Kingshott, CA | 1 |
| Peters, AL | 1 |
| Day, BL | 1 |
| Thompson, AJ | 1 |
| Ciccarelli, O | 1 |
| Sharma, U | 1 |
| Upadhyay, D | 1 |
| Mewar, S | 1 |
| Mishra, A | 1 |
| Das, P | 1 |
| Gupta, SD | 1 |
| Dwivedi, SN | 1 |
| Makharia, GK | 1 |
| Jagannathan, NR | 1 |
| Bravo-Oro, A | 1 |
| Acosta-Yebra, D | 1 |
| Grimaldo-Zapata, IP | 1 |
| Reyes-Vaca, G | 1 |
| Regier, DS | 1 |
| Kwon, HJ | 1 |
| Johnston, J | 1 |
| Golas, G | 1 |
| Yang, S | 1 |
| Wiggs, E | 1 |
| Latour, Y | 1 |
| Thomas, S | 1 |
| Portner, C | 1 |
| Adams, D | 1 |
| Vezina, G | 1 |
| Baker, EH | 1 |
| Tifft, CJ | 1 |
| Giovagnoli, AR | 1 |
| Aresi, A | 1 |
| Reati, F | 1 |
| Riva, A | 1 |
| Gobbo, C | 1 |
| Bizzi, A | 1 |
| Kantarci, K | 1 |
| Weigand, SD | 1 |
| Przybelski, SA | 1 |
| Shiung, MM | 1 |
| Whitwell, JL | 1 |
| Negash, S | 1 |
| Knopman, DS | 1 |
| Boeve, BF | 1 |
| O'Brien, PC | 1 |
| Petersen, RC | 1 |
| Jack, CR | 1 |
| García Santos, JM | 1 |
| Fuentes, LJ | 1 |
| Vidal, JB | 1 |
| Carrillo, A | 1 |
| Antequera, M | 1 |
| Campoy, G | 1 |
| Antúnez, C | 1 |
| Torres del Río, S | 1 |
| García-Sevilla, J | 1 |
| Ortega, G | 1 |
| Georgoulopoulou, E | 1 |
| Gellera, C | 1 |
| Bragato, C | 1 |
| Sola, P | 1 |
| Chiari, A | 1 |
| Bernabei, C | 1 |
| Mandrioli, J | 1 |
| Hui, JJ | 1 |
| Zhang, ZJ | 1 |
| Liu, SS | 1 |
| Xi, GJ | 1 |
| Zhang, XR | 1 |
| Teng, GJ | 1 |
| Chan, KC | 1 |
| Wu, EX | 1 |
| Nie, BB | 1 |
| Shan, BC | 1 |
| Li, LJ | 1 |
| Reynolds, GP | 1 |
| Garcia-Martinez, R | 1 |
| Rovira, A | 1 |
| Alonso, J | 1 |
| Jacas, C | 1 |
| Simón-Talero, M | 1 |
| Chavarria, L | 1 |
| Vargas, V | 1 |
| Córdoba, J | 1 |
| Pietroboni, AM | 1 |
| Fumagalli, GG | 1 |
| Ghezzi, L | 1 |
| Fenoglio, C | 1 |
| Cortini, F | 1 |
| Serpente, M | 1 |
| Cantoni, C | 1 |
| Rotondo, E | 1 |
| Corti, P | 1 |
| Carecchio, M | 1 |
| Bassi, M | 1 |
| Bresolin, N | 1 |
| Galbiati, D | 1 |
| Galimberti, D | 1 |
| Scarpini, E | 1 |
| Wu, WE | 2 |
| Hirsch, J | 1 |
| Achtnichts, L | 2 |
| Amann, M | 2 |
| Algarzae, N | 1 |
| Hebron, M | 1 |
| Miessau, M | 1 |
| Moussa, CE | 1 |
| Sarchielli, P | 1 |
| Presciutti, O | 1 |
| Tarducci, R | 1 |
| Gobbi, G | 1 |
| Alberti, A | 1 |
| Pelliccioli, GP | 1 |
| Chiarini, P | 1 |
| Gallai, V | 1 |
| Zhai, P | 1 |
| Pagan, F | 1 |
| Statland, J | 1 |
| Butman, JA | 1 |
| Floeter, MK | 1 |
| Lassmann, H | 1 |
| Petroff, OA | 1 |
| Errante, LD | 1 |
| Kim, JH | 1 |
| Spencer, DD | 1 |
| Christodoulou, C | 1 |
| Krupp, LB | 1 |
| Liang, Z | 1 |
| Huang, W | 1 |
| Melville, P | 1 |
| Roque, C | 1 |
| Scherl, WF | 1 |
| Morgan, T | 1 |
| MacAllister, WS | 1 |
| Tudorica, LA | 1 |
| Li, X | 1 |
| Roche, P | 1 |
| Peyster, R | 1 |
| Konaka, K | 1 |
| Ueda, H | 1 |
| Li, JY | 1 |
| Matsumoto, M | 1 |
| Sakoda, S | 1 |
| Yanagihara, T | 2 |
| Antel, JP | 4 |
| Kita, M | 1 |
| Zamvil, SS | 1 |
| Goodkin, DE | 1 |
| Wylezinska, M | 1 |
| Cifelli, A | 1 |
| Jezzard, P | 1 |
| Palace, J | 1 |
| Alecci, M | 1 |
| Matthews, PM | 2 |
| Patel, SH | 1 |
| Inglese, M | 5 |
| Glosser, G | 1 |
| Kolson, DL | 2 |
| Grossman, RI | 4 |
| De Stefano, N | 3 |
| Guidi, L | 1 |
| Stromillo, ML | 1 |
| Bartolozzi, ML | 1 |
| Federico, A | 1 |
| Ge, Y | 1 |
| Markowitz, CE | 1 |
| Brass, SD | 1 |
| Narayanan, S | 3 |
| Lapierre, Y | 1 |
| Collins, L | 1 |
| Arnold, DL | 4 |
| Page, RA | 1 |
| Davie, CA | 2 |
| MacManus, D | 1 |
| Miszkiel, KA | 1 |
| Walshe, JM | 1 |
| Miller, DH | 3 |
| Lees, AJ | 1 |
| Schapira, AH | 1 |
| Lodi, R | 1 |
| Tonon, C | 1 |
| Vignatelli, L | 1 |
| Iotti, S | 1 |
| Montagna, P | 1 |
| Barbiroli, B | 1 |
| Plazzi, G | 1 |
| Chao, LL | 1 |
| Schuff, N | 6 |
| Kramer, JH | 2 |
| Du, AT | 3 |
| Capizzano, AA | 2 |
| O'Neill, J | 2 |
| Wolkowitz, OM | 2 |
| Jagust, WJ | 1 |
| Chui, HC | 1 |
| Miller, BL | 1 |
| Yaffe, K | 2 |
| Weiner, MW | 6 |
| Biernacki, K | 1 |
| Blain, M | 1 |
| Prat, A | 1 |
| Briellmann, RS | 1 |
| Wellard, RM | 1 |
| Jackson, GD | 1 |
| Falini, A | 2 |
| Bozzali, M | 1 |
| Magnani, G | 1 |
| Pero, G | 1 |
| Gambini, A | 1 |
| Benedetti, B | 2 |
| Mossini, R | 1 |
| Franceschi, M | 1 |
| Comi, G | 2 |
| Scotti, G | 2 |
| Filippi, M | 2 |
| Rovaris, M | 1 |
| Gallo, A | 1 |
| Rossi, P | 1 |
| Comola, M | 1 |
| Nusbaum, AO | 1 |
| Pastores, GM | 1 |
| Gianutsos, J | 1 |
| Kolodny, EH | 1 |
| Kin, T | 1 |
| Hirano, M | 1 |
| Taoka, T | 1 |
| Takamure, M | 1 |
| Furiya, Y | 1 |
| Kichikawa, K | 1 |
| Ueno, S | 1 |
| Huisman, TA | 1 |
| Klein, A | 1 |
| Werner, B | 1 |
| Straube, T | 1 |
| Boltshauser, E | 1 |
| Lantz, G | 1 |
| Seeck, M | 1 |
| Lazeyras, F | 1 |
| Garrard, P | 1 |
| Schott, JM | 1 |
| MacManus, DG | 1 |
| Hodges, JR | 1 |
| Fox, NC | 1 |
| Waldman, AD | 1 |
| Janson, CG | 1 |
| McPhee, SW | 1 |
| Francis, J | 1 |
| Shera, D | 1 |
| Assadi, M | 1 |
| Freese, A | 1 |
| Hurh, P | 1 |
| Haselgrove, J | 1 |
| Wang, DJ | 1 |
| Bilaniuk, L | 1 |
| Leone, P | 1 |
| Bartsch, AJ | 1 |
| Homola, G | 1 |
| Biller, A | 1 |
| Smith, SM | 1 |
| Weijers, HG | 1 |
| Wiesbeck, GA | 1 |
| Jenkinson, M | 1 |
| Solymosi, L | 1 |
| Bendszus, M | 1 |
| Oberndorfer, TA | 1 |
| Herbert, J | 1 |
| Cohen, BA | 1 |
| Rusinek, H | 1 |
| Rüsch, N | 1 |
| Tebartz van Elst, L | 1 |
| Valerius, G | 1 |
| Büchert, M | 1 |
| Thiel, T | 1 |
| Ebert, D | 1 |
| Hennig, J | 1 |
| Olbrich, HM | 1 |
| Roc, AC | 1 |
| Ances, BM | 1 |
| Chawla, S | 1 |
| Korczykowski, M | 1 |
| Wolf, RL | 1 |
| Detre, JA | 1 |
| Poptani, H | 1 |
| Schubert, MI | 1 |
| Kalisch, R | 1 |
| Sotiropoulos, I | 1 |
| Catania, C | 1 |
| Sousa, N | 1 |
| Almeida, OF | 1 |
| Auer, DP | 2 |
| Gazdzinski, S | 1 |
| Durazzo, TC | 1 |
| Yeh, PH | 1 |
| Hardin, D | 1 |
| Banys, P | 1 |
| Meyerhoff, DJ | 1 |
| Neylan, TC | 2 |
| Fox-Bosetti, S | 1 |
| Lenoci, M | 1 |
| Samuelson, KW | 1 |
| Studholme, C | 1 |
| Marmar, CR | 2 |
| Güngör, S | 1 |
| Akinci, A | 1 |
| Firat, AK | 1 |
| Tabel, Y | 1 |
| Alkan, A | 1 |
| Summers, M | 1 |
| Swanton, J | 1 |
| Fernando, K | 1 |
| Dalton, C | 1 |
| Cipolotti, L | 1 |
| Ron, MA | 1 |
| Döhlinger, S | 1 |
| Hauser, TK | 1 |
| Borkert, J | 1 |
| Luft, AR | 1 |
| Schulz, JB | 1 |
| Azevedo, D | 1 |
| Tatsch, M | 1 |
| Hototian, SR | 1 |
| Bazzarella, MC | 1 |
| Castro, CC | 1 |
| Bottino, CM | 1 |
| Perry, TL | 3 |
| Kish, SJ | 1 |
| Hansen, S | 3 |
| Currier, RD | 3 |
| Plaitakis, A | 1 |
| Berl, S | 1 |
| Sreeramulu Chetty, C | 1 |
| Chandramohan Naidu, R | 1 |
| Sreenivasa Moorthy, K | 1 |
| Swami, KS | 1 |
| Martin, PR | 1 |
| Gibbs, SJ | 1 |
| Nimmerrichter, AA | 1 |
| Riddle, WR | 1 |
| Welch, LW | 1 |
| Willcott, MR | 1 |
| Wenning, GK | 1 |
| Barker, GJ | 1 |
| Tofts, PS | 1 |
| Kendall, BE | 2 |
| Quinn, N | 1 |
| McDonald, WI | 1 |
| Marsden, CD | 1 |
| Sibbitt, WL | 2 |
| Haseler, LJ | 1 |
| Griffey, RH | 1 |
| Hart, BL | 2 |
| Sibbitt, RR | 1 |
| Matwiyoff, NA | 1 |
| Tedeschi, G | 1 |
| Bertolino, A | 1 |
| Massaquoi, SG | 1 |
| Campbell, G | 1 |
| Patronas, NJ | 1 |
| Bonavita, S | 2 |
| Barnett, AS | 1 |
| Alger, JR | 1 |
| Hallett, M | 1 |
| Wu, G | 1 |
| Meier, SA | 1 |
| Knabe, DA | 1 |
| Ende, GR | 1 |
| Laxer, KD | 1 |
| Knowlton, RC | 1 |
| Matson, GB | 1 |
| Fein, G | 2 |
| Perros, P | 1 |
| Deary, IJ | 1 |
| Sellar, RJ | 1 |
| Best, JJ | 1 |
| Frier, BM | 1 |
| Federico, F | 1 |
| Simone, IL | 1 |
| Lucivero, V | 1 |
| Iliceto, G | 1 |
| De Mari, M | 1 |
| Giannini, P | 1 |
| Mezzapesa, DM | 1 |
| Tarantino, A | 1 |
| Lamberti, P | 1 |
| Amend, D | 1 |
| Ezekiel, F | 1 |
| Steinman, SK | 1 |
| Tanabe, J | 1 |
| Norman, D | 2 |
| Jagust, W | 2 |
| Mastrianni, JA | 1 |
| Maeda, H | 1 |
| Furune, S | 1 |
| Nomura, K | 1 |
| Kitou, O | 1 |
| Ando, Y | 1 |
| Negoro, T | 1 |
| Watanabe, K | 1 |
| van der Knaap, MS | 2 |
| Bakker, HD | 1 |
| Valk, J | 2 |
| Harrison, MJ | 1 |
| Newman, SP | 1 |
| Hall-Craggs, MA | 1 |
| Fowler, CJ | 1 |
| Miller, R | 1 |
| Paley, M | 1 |
| Wilkinson, I | 1 |
| Sweeney, B | 1 |
| Lunn, S | 1 |
| Carter, S | 1 |
| Williams, I | 1 |
| Schlemmer, HP | 1 |
| Möckel, R | 1 |
| Marcus, A | 1 |
| Hentschel, F | 1 |
| Göpel, C | 1 |
| Becker, G | 1 |
| Köpke, J | 1 |
| Gückel, F | 1 |
| Schmidt, MH | 1 |
| Georgi, M | 1 |
| Seitz, D | 1 |
| Widmann, U | 1 |
| Seeger, U | 1 |
| Nägele, T | 1 |
| Klose, U | 1 |
| Mann, K | 1 |
| Grodd, W | 1 |
| Akiguchi, I | 1 |
| Nakano, S | 1 |
| Shiino, A | 1 |
| Kimura, R | 1 |
| Inubushi, T | 1 |
| Handa, J | 1 |
| Nakamura, M | 2 |
| Tanaka, M | 1 |
| Oka, N | 1 |
| Kimura, J | 1 |
| Terakawa, H | 1 |
| Abe, K | 1 |
| Watanabe, Y | 1 |
| Fujita, N | 1 |
| Hirabuki, N | 1 |
| Lundbom, N | 1 |
| Barnett, A | 1 |
| Patronas, N | 1 |
| Rajapakse, J | 1 |
| Di Chiro, G | 1 |
| Li, LM | 1 |
| Cendes, F | 1 |
| Antel, SB | 1 |
| Andermann, F | 1 |
| Serles, W | 1 |
| Dubeau, F | 1 |
| Olivier, A | 1 |
| Ferrante, RJ | 1 |
| Andreassen, OA | 1 |
| Jenkins, BG | 1 |
| Dedeoglu, A | 1 |
| Kuemmerle, S | 1 |
| Kubilus, JK | 1 |
| Kaddurah-Daouk, R | 1 |
| Hersch, SM | 1 |
| Beal, MF | 1 |
| Paty, DW | 1 |
| Francis, GS | 1 |
| Arnaoutelis, R | 1 |
| Tartaglia, MC | 1 |
| Villarreal, G | 1 |
| King, CY | 1 |
| Bjartmar, C | 1 |
| Trapp, BD | 1 |
| Sijens, PE | 1 |
| Den Heijer, T | 1 |
| De Leeuw, FE | 1 |
| De Groot, JC | 1 |
| Achten, E | 1 |
| Heijboer, RJ | 1 |
| Hofman, A | 1 |
| Breteler, MM | 1 |
| Oudkerk, M | 1 |
| Wilke, M | 1 |
| Grabner, A | 1 |
| Heidenreich, JO | 1 |
| Bronisch, T | 1 |
| Wetter, TC | 1 |
| Lenoci, MA | 1 |
| Weiss, DS | 1 |
| Jung, RE | 1 |
| Yeo, RA | 1 |
| Ford, CC | 1 |
| Brooks, WM | 1 |
| Amend, DL | 1 |
| Kramer, J | 1 |
| Miller, B | 1 |
| Berry, K | 1 |
| MacLean, J | 1 |
| Wang, Z | 1 |
| Bogdan, AR | 1 |
| Zimmerman, RA | 1 |
| Gusnard, DA | 1 |
| Leigh, JS | 1 |
| Ohene-Frempong, K | 1 |
| van der Grond, J | 1 |
| Luyten, PR | 1 |
| den Hollander, JA | 1 |
| Nauta, JJ | 1 |
| Whitehouse, PJ | 1 |
| Muramoto, O | 1 |
| Troncoso, JC | 1 |
| Kanazawa, I | 1 |
| Kvittingen, EA | 1 |
| Guldal, G | 1 |
| Børsting, S | 1 |
| Skalpe, IO | 1 |
| Stokke, O | 1 |
| Jellum, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| MRI Biomarkers of Risk in Sedentary and Exercise Trained Humans[NCT02729428] | 71 participants (Actual) | Observational | 2016-04-30 | Completed | |||
| Coenzyme Q10 in Huntington's Disease (HD)[NCT00608881] | Phase 3 | 609 participants (Actual) | Interventional | 2008-03-31 | Terminated (stopped due to Futility analysis failed to showed likelihoo of benefit of CoQ 2400 mg/day.) | ||
| Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)[NCT00712426] | Phase 3 | 553 participants (Actual) | Interventional | 2009-09-30 | Terminated (stopped due to Results of an interim analysis showed that it was unlikely that creatine was effective in slowing loss of function in early symptomatic Huntington's Disease.) | ||
| Creatine Safety and Tolerability in Premanifest HD: PRECREST[NCT00592995] | Phase 2 | 64 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| The Effectiveness of Game-Based Virtual Reality Approach in Patients With Multiple Sclerosis[NCT04212689] | 40 participants (Anticipated) | Interventional | 2020-01-20 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Unified Huntington's Disease Rating Scale (UHDRS) behavioral subscale assesses frequency and severity of psychiatric-related symptoms, including depressed mood, apathy, low self-esteem/guilt, suicidal thoughts, anxiety, irritable behavior, aggressive behavior, obsessional thinking, compulsive behavior, delusions, and hallucinations. A total score was calculated by summing up all the individual behavioral frequency items (range 0-56) with higher scores representing more severe behavioral impairment. (NCT00608881)
Timeframe: Baseline and Month 60
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | 1.39 |
| B - Placebo | 1.43 |
The Unified Huntington's Disease Rating Scale (UHDRS) behavioral subscale assesses frequency and severity of psychiatric-related symptoms, including depressed mood, apathy, low self-esteem/guilt, suicidal thoughts, anxiety, irritable behavior, aggressive behavior, obsessional thinking, compulsive behavior, delusions, and hallucinations. The total score is the sum of the product of the individual behavioral frequency and severity items (range 0-176) with higher scores representing more severe behavioral impairment. (NCT00608881)
Timeframe: Baseline and Month 60
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | 4.29 |
| B - Placebo | 5.06 |
"The functional assessment checklist includes 25 questions about common daily tasks. A score of 1 is given for each yes reply and a score of 0 is given for each no reply (scale range is 0-25). Higher scores indicate better functioning." (NCT00608881)
Timeframe: Baseline and Month 60
| Intervention | units on a scale (Mean) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | -7.93 |
| B - Placebo | -8.02 |
The independence scale assesses independence on a 0 to 100 scale with higher scores indicating better functioning. (NCT00608881)
Timeframe: Baseline and Month 60
| Intervention | units on a scale (Mean) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | -26.30 |
| B - Placebo | -24.86 |
Stroop Interference Test - color naming score is the total number of correct colors identified in 45 seconds and reflects processing speed. (NCT00608881)
Timeframe: Baseline and Month 60
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | -14.21 |
| B - Placebo | -14.51 |
Stroop Interference Test - interference score is the total number of correct items identified in 45 seconds and reflects an executive measure of inhibitory ability. (NCT00608881)
Timeframe: Baseline and Month 60
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | -7.57 |
| B - Placebo | -8.61 |
Stroop Interference Test - word reading score is the total number of correct words read in 45 seconds and reflects processing speed. (NCT00608881)
Timeframe: Baseline and Month 60
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | -15.25 |
| B - Placebo | -19.13 |
The SDMT assesses attention, visuoperceptual processing, working memory, and cognitive/psychomotor speed. The score is the number of correctly paired abstract symbols and specific numbers in 90 seconds with higher scores indicating better cognitive functioning. (NCT00608881)
Timeframe: Baseline and Month 60
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | -10.95 |
| B - Placebo | -11.36 |
TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: Baseline and Month 60
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | -4.53 |
| B - Placebo | -4.76 |
The motor section of the Unified Huntington's Disease Rating Scale (UHDRS) assesses motor features of Huntington disease with standardized ratings of oculomotor function, dysarthria, chorea, dystonia, gait, and postural stability. The total motor score is the sum of all the individual motor ratings, with higher scores (124) indicating more severe motor impairment than lower scores. The score ranges from 0 to 124. (NCT00608881)
Timeframe: Baseline and Month 60
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | 18.06 |
| B - Placebo | 19.18 |
The verbal fluency test is typically considered a measure of executive function. The score is the number of correct words produced across three 1-minute trials. (NCT00608881)
Timeframe: Baseline and Month 60
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | -5.07 |
| B - Placebo | -4.47 |
The primary outcome variable at the start of the trial was the change in TFC score from baseline to Month 60. The Data and Safety Monitoring Board recommended to the trial leadership that they reconsider how they accommodate missing data from subjects who die in their primary analysis of the change in TFC score. Based on these recommendations, the trial leadership changed the primary analysis to that of a joint rank approach. TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: 5 years
| Intervention | rank (Mean) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | 303.3 |
| B - Placebo | 306.7 |
(NCT00608881)
Timeframe: 5 years
| Intervention | participants completing study on drug (Number) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | 98 |
| B - Placebo | 108 |
TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: 5 years
| Intervention | days to event (Median) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | 917 |
| B - Placebo | 911 |
TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: 5 years
| Intervention | days to event (Median) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | 553 |
| B - Placebo | 549 |
6 reviews available for aspartic acid and Atrophy
| Article | Year |
|---|---|
Systematic review of in-vivo neuro magnetic resonance spectroscopy for the assessment of posttraumatic stress disorder.
Topics: Aspartic Acid; Atrophy; Brain; Creatine; Female; gamma-Aminobutyric Acid; Gyrus Cinguli; Hippocampus | 2018 |
[Reversible cortical atrophy secondary to anti-NMDA receptor antibody encephalitis].
Topics: Anti-N-Methyl-D-Aspartate Receptor Encephalitis; Anticonvulsants; Aphasia, Broca; Aspartic Acid; Atr | 2015 |
Imaging neuronal and axonal degeneration in multiple sclerosis.
Topics: Aspartic Acid; Atrophy; Axons; Brain; Humans; Magnetic Resonance Spectroscopy; Multiple Sclerosis; N | 2003 |
Seizure-associated abnormalities in epilepsy: evidence from MR imaging.
Topics: Adult; Aspartic Acid; Atrophy; Brain; Brain Diseases; Brain Edema; Choline; Creatine; Diffusion Magn | 2005 |
Brain imaging in posttraumatic stress disorder.
Topics: Amygdala; Arousal; Aspartic Acid; Atrophy; Brain; Chronic Disease; Cognition; Fear; Hippocampus; Hum | 2001 |
Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences.
Topics: Aspartic Acid; Atrophy; Axons; Brain; Humans; Magnetic Resonance Imaging; Magnetic Resonance Spectro | 2001 |
4 trials available for aspartic acid and Atrophy
| Article | Year |
|---|---|
Cognitive performance and MR markers of cerebral injury in cognitively impaired MS patients.
Topics: Adult; Aspartic Acid; Atrophy; Axons; Biomarkers; Cerebral Cortex; Choline; Cognition Disorders; Cre | 2003 |
Axonal damage in multiple sclerosis patients with high versus low expanded disability status scale score.
Topics: Adult; Aspartic Acid; Atrophy; Axons; Biomarkers; Brain; Disability Evaluation; Humans; Magnetic Res | 2004 |
Proton MR spectroscopy and MRI-volumetry in mild traumatic brain injury.
Topics: Adult; Age Factors; Aspartic Acid; Atrophy; Axons; Brain; Brain Injuries; Female; Glasgow Coma Scale | 2007 |
Proton spectroscopy in Alzheimer's disease and cognitive impairment no dementia: a community-based study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Atrophy; Brain; Choline; Cognition Disord | 2008 |
92 other studies available for aspartic acid and Atrophy
| Article | Year |
|---|---|
Brain MRI features of anti-N-methyl-D-aspartate (anti-NMDA) receptor encephalitis secondary to central nervous system infection in adult patients.
Topics: Adult; Anti-N-Methyl-D-Aspartate Receptor Encephalitis; Aspartic Acid; Atrophy; Brain; Central Nervo | 2023 |
Metabolomic Profiling of Asparagine Deprivation in Asparagine Synthetase Deficiency Patient-Derived Cells.
Topics: Amino Acid Metabolism, Inborn Errors; Asparagine; Aspartate-Ammonia Ligase; Aspartic Acid; Atrophy; | 2023 |
Pathological Bergmann glia alterations and disrupted calcium dynamics in ataxic Canavan disease mice.
Topics: Animals; Aspartic Acid; Ataxia; Atrophy; Calcium; Canavan Disease; Child; Humans; Infant; Mice; Neur | 2023 |
Short echo-time Magnetic Resonance Spectroscopy in ALS, simultaneous quantification of glutamate and GABA at 3 T.
Topics: Aged; Amyotrophic Lateral Sclerosis; Aspartic Acid; Atrophy; Choline; Creatine; Disease Progression; | 2019 |
Antisense Oligonucleotide Reverses Leukodystrophy in Canavan Disease Mice.
Topics: Acetyltransferases; Amidohydrolases; Animals; Aspartic Acid; Ataxia; Atrophy; Canavan Disease; Cereb | 2020 |
Global brain volume and N-acetyl-aspartate decline over seven decades of normal aging.
Topics: Aged; Aged, 80 and over; Aspartic Acid; Atrophy; Brain; Female; Gray Matter; Healthy Aging; Humans; | 2021 |
Dysregulation of energy metabolism in multiple sclerosis measured in vivo with diffusion-weighted spectroscopy.
Topics: Adult; Aspartic Acid; Atrophy; Creatine; Diffusion Magnetic Resonance Imaging; Energy Metabolism; Fe | 2018 |
Whole brain neuronal abnormalities in focal epilepsy quantified with proton MR spectroscopy.
Topics: Adult; Aspartic Acid; Atrophy; Brain; Cohort Studies; Epilepsies, Partial; Female; Humans; Magnetic | 2018 |
[Developmental amnesia and early brain damage: neuropsychology and neuroimaging].
Topics: Adolescent; Amnesia; Aspartic Acid; Atrophy; Cerebral Palsy; Child; Choline; Creatine; Female; Fetal | 2018 |
Increased glutamate and deep brain atrophy can predict the severity of multiple sclerosis.
Topics: Adult; Aspartic Acid; Atrophy; Disease Progression; Female; Glutamic Acid; Humans; Magnetic Resonanc | 2019 |
Increased right amygdala metabolite concentrations in the absence of atrophy in children and adolescents with PTSD.
Topics: Adolescent; Amygdala; Aspartic Acid; Atrophy; Biomarkers; Child; Choline; Creatine; Cross-Sectional | 2019 |
Neurochemical correlates of caudate atrophy in Huntington's disease.
Topics: Adult; Aged; Aspartic Acid; Atrophy; Caudate Nucleus; Female; Glutamic Acid; Humans; Huntington Dise | 2014 |
Magnetic resonance spectroscopy markers of disease progression in multiple sclerosis.
Topics: Adult; Aspartic Acid; Atrophy; Biomarkers; Case-Control Studies; Disability Evaluation; Disease Prog | 2014 |
Evidence for early neurodegeneration in the cervical cord of patients with primary progressive multiple sclerosis.
Topics: Adolescent; Adult; Aged; Aspartic Acid; Atrophy; Brain; Case-Control Studies; Cervical Cord; Disabil | 2015 |
Metabolic abnormalities of gastrointestinal mucosa in celiac disease: An in vitro proton nuclear magnetic resonance spectroscopy study.
Topics: Adolescent; Adult; Amino Acids; Aspartic Acid; Atrophy; Biomarkers; Celiac Disease; Citric Acid Cycl | 2015 |
MRI/MRS as a surrogate marker for clinical progression in GM1 gangliosidosis.
Topics: Adolescent; Age of Onset; Aspartic Acid; Atrophy; beta-Galactosidase; Cerebellum; Cerebrum; Child; C | 2016 |
The neuropsychological and neuroradiological correlates of slowly progressive visual agnosia.
Topics: Agnosia; Aspartic Acid; Atrophy; Brain; Brain Mapping; Disease Progression; Energy Metabolism; Femal | 2009 |
Risk of dementia in MCI: combined effect of cerebrovascular disease, volumetric MRI, and 1H MRS.
Topics: Aged; Aged, 80 and over; Aspartic Acid; Atrophy; Biomarkers; Brain; Cerebrovascular Disorders; Cogni | 2009 |
Posterior paralimbic and frontal metabolite impairments in asymptomatic hypertension with different treatment outcomes.
Topics: Aged; Antihypertensive Agents; Aspartic Acid; Atrophy; Brain; Brain Chemistry; Cerebral Hemorrhage; | 2010 |
A novel SOD1 mutation in a young amyotrophic lateral sclerosis patient with a very slowly progressive clinical course.
Topics: Adult; Amino Acid Substitution; Amyotrophic Lateral Sclerosis; Aspartic Acid; Atrophy; Disease Progr | 2010 |
Hippocampal neurochemistry is involved in the behavioural effects of neonatal maternal separation and their reversal by post-weaning environmental enrichment: a magnetic resonance study.
Topics: Animals; Aspartic Acid; Atrophy; Choice Behavior; Environment; Female; Hippocampus; Magnetic Resonan | 2011 |
Hepatic encephalopathy is associated with posttransplant cognitive function and brain volume.
Topics: Adult; Aspartic Acid; Atrophy; Brain; Chi-Square Distribution; Cognition; Cognition Disorders; Femal | 2011 |
Phenotypic heterogeneity of the GRN Asp22fs mutation in a large Italian kindred.
Topics: Age of Onset; Aged; Aspartic Acid; Atrophy; Cognition Disorders; Female; Frontotemporal Dementia; Hu | 2011 |
Whole brain N-acetylaspartate concentration is conserved throughout normal aging.
Topics: Adult; Aged; Aged, 80 and over; Aging; Aspartic Acid; Atrophy; Biomarkers; Brain; Brain Chemistry; F | 2012 |
Parkin prevents cortical atrophy and Aβ-induced alterations of brain metabolism: ¹³C NMR and magnetic resonance imaging studies in AD models.
Topics: Adaptor Proteins, Signal Transducing; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein | 2012 |
The whole-brain N-acetylaspartate correlates with education in normal adults.
Topics: Aged; Aged, 80 and over; Aspartic Acid; Atrophy; Brain; Cognitive Reserve; Educational Status; Femal | 2012 |
Localized (1)H magnetic resonance spectroscopy in mainly cortical gray matter of patients with multiple sclerosis.
Topics: Adult; Aspartic Acid; Atrophy; Creatine; Disease Progression; Female; Humans; Magnetic Resonance Spe | 2002 |
Primary lateral sclerosis: A heterogeneous disorder composed of different subtypes?
Topics: Adult; Aspartic Acid; Atrophy; Brain Stem; Choline; Creatinine; Disease Progression; Evoked Potentia | 2003 |
Brain damage when multiple sclerosis is diagnosed clinically.
Topics: Aspartic Acid; Atrophy; Brain; Brain Damage, Chronic; Humans; Magnetic Resonance Imaging; Magnetic R | 2003 |
N-acetyl-aspartate, total creatine, and myo-inositol in the epileptogenic human hippocampus.
Topics: Adolescent; Adult; Anterior Temporal Lobectomy; Aspartic Acid; Atrophy; Creatine; Epilepsy, Temporal | 2003 |
N-acetylaspartate to total creatine ratio in the hippocampal CA1 sector after transient cerebral ischemia in gerbils: influence of neuronal elements, reactive gliosis, and tissue atrophy.
Topics: Animals; Aspartic Acid; Astrocytes; Atrophy; Cell Count; Common Variable Immunodeficiency; Creatine; | 2003 |
MRI lesion volume heterogeneity in primary progressive MS in relation with axonal damage and brain atrophy.
Topics: Aspartic Acid; Atrophy; Brain; Case-Control Studies; Creatinine; Female; Humans; Magnetic Resonance | 2003 |
Thalamic neurodegeneration in relapsing-remitting multiple sclerosis.
Topics: Adult; Aspartic Acid; Atrophy; Biomarkers; Body Water; Female; Humans; Magnetic Resonance Imaging; M | 2003 |
Whole-brain N-acetylaspartate level and cognitive performance in HIV infection.
Topics: Adult; AIDS Dementia Complex; Aspartic Acid; Atrophy; Brain; Disease Progression; Energy Metabolism; | 2003 |
Neuronal cell injury precedes brain atrophy in multiple sclerosis.
Topics: Adult; Aspartic Acid; Atrophy; Brain; Brain Chemistry; Disease Progression; Female; Humans; Magnetic | 2004 |
Clinical correlation of brain MRI and MRS abnormalities in patients with Wilson disease.
Topics: Adult; Aged; Aspartic Acid; Atrophy; Brain; Brain Chemistry; Chelation Therapy; Copper; Dipeptides; | 2004 |
In vivo evidence of neuronal loss in the hypothalamus of narcoleptic patients.
Topics: Adolescent; Adult; Aged; Aspartic Acid; Atrophy; Cataplexy; Creatine; Female; Humans; Hypothalamus; | 2004 |
Reduced medial temporal lobe N-acetylaspartate in cognitively impaired but nondemented patients.
Topics: Aged; Aspartic Acid; Atrophy; Cognition Disorders; Dementia; Female; Hippocampus; Humans; Magnetic R | 2005 |
Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis.
Topics: Adult; Aspartic Acid; Astrocytes; Atrophy; CD3 Complex; Cell Communication; Cells, Cultured; Central | 2005 |
A whole brain MR spectroscopy study from patients with Alzheimer's disease and mild cognitive impairment.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Atrophy; Brain; Brain Chemistry; Cognition Disorders; Female | 2005 |
Axonal injury and overall tissue loss are not related in primary progressive multiple sclerosis.
Topics: Adult; Aged; Aspartic Acid; Atrophy; Axons; Biomarkers; Brain; Female; Humans; Magnetic Resonance Sp | 2005 |
MR imaging and proton spectroscopy of neuronal injury in late-onset GM2 gangliosidosis.
Topics: Adult; Aspartic Acid; Atrophy; Axons; Brain; Case-Control Studies; Cerebellum; Creatine; Female; Gan | 2005 |
Proton MR spectroscopy of adult-onset dentatorubral-pallidoluysian atrophy.
Topics: Aged; Aspartic Acid; Atrophy; Basal Ganglia Diseases; Case-Control Studies; Choline; Creatine; Denta | 2005 |
Serial MR imaging, diffusion tensor imaging, and MR spectroscopic findings in a child with progressive encephalopathy, edema, hypsarrhythmia, and optic atrophy (PEHO) syndrome.
Topics: Aspartic Acid; Atrophy; Brain Diseases; Brain Edema; Cerebellum; Child; Choline; Creatine; Diffusion | 2006 |
Extent of preoperative abnormalities and focus lateralization predict postoperative normalization of contralateral 1H-magnetic resonance spectroscopy metabolite levels in patients with temporal lobe epilepsy.
Topics: Adult; Aspartic Acid; Atrophy; Choline; Creatine; Dominance, Cerebral; Electroencephalography; Energ | 2006 |
Posterior cingulate neurometabolite profiles and clinical phenotype in frontotemporal dementia.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Atrophy; Dementia; Diagnosis, Differential; Female; Frontal | 2006 |
Natural history of Canavan disease revealed by proton magnetic resonance spectroscopy (1H-MRS) and diffusion-weighted MRI.
Topics: Age Factors; Aspartic Acid; Atrophy; Brain; Canavan Disease; Case-Control Studies; Child, Preschool; | 2006 |
Manifestations of early brain recovery associated with abstinence from alcoholism.
Topics: Adult; Alcoholism; Aspartic Acid; Atrophy; Attention; Brain; Brain Chemistry; Cerebellum; Choline; C | 2007 |
Reproducibility of three whole-brain N-acetylaspartate decline cohorts in relapsing-remitting multiple sclerosis.
Topics: Adult; Aspartic Acid; Atrophy; Brain; Cohort Studies; Female; Humans; Magnetic Resonance Spectroscop | 2007 |
Neurochemical and structural correlates of executive dysfunction in schizophrenia.
Topics: Adult; Amygdala; Aspartic Acid; Atrophy; Brain; Cognition Disorders; Dominance, Cerebral; Female; Gl | 2008 |
Detection of human immunodeficiency virus induced inflammation and oxidative stress in lenticular nuclei with magnetic resonance spectroscopy despite antiretroviral therapy.
Topics: Adult; AIDS Dementia Complex; Antiretroviral Therapy, Highly Active; Aspartic Acid; Atrophy; Biomark | 2007 |
Effects of altered corticosteroid milieu on rat hippocampal neurochemistry and structure--an in vivo magnetic resonance spectroscopy and imaging study.
Topics: Animals; Aspartic Acid; Atrophy; Choline; Creatine; Dexamethasone; Energy Metabolism; Glucocorticoid | 2008 |
Chronic cigarette smoking modulates injury and short-term recovery of the medial temporal lobe in alcoholics.
Topics: Adult; Aged; Alcohol Amnestic Disorder; Alcoholism; Aspartic Acid; Atrophy; Choline; Cross-Sectional | 2008 |
Abnormal N-acetylaspartate in hippocampus and anterior cingulate in posttraumatic stress disorder.
Topics: Adult; Alcoholism; Algorithms; Aspartic Acid; Atrophy; Combat Disorders; Comorbidity; Conditioning, | 2008 |
Neuroimaging findings in hyperargininemia.
Topics: Arginine; Aspartic Acid; Atrophy; Basal Ganglia Cerebrovascular Disease; Brain Diseases; Cerebellum; | 2008 |
Cognitive impairment in multiple sclerosis can be predicted by imaging early in the disease.
Topics: Adolescent; Adult; Aspartic Acid; Atrophy; Brain; Cerebral Ventricles; Cognition Disorders; Cohort S | 2008 |
Magnetic resonance imaging in spinocerebellar ataxias.
Topics: Aspartic Acid; Ataxin-1; Ataxin-3; Ataxins; Atrophy; Brain; Cerebellum; Humans; Magnetic Resonance I | 2008 |
Neurotransmitter amino acids in dominantly inherited cerebellar disorders.
Topics: Amino Acids; Aspartic Acid; Atrophy; Cerebellar Diseases; gamma-Aminobutyric Acid; Glutamates; Human | 1981 |
Oral glutamate loading in disorders with spinocerebellar and extrapyramidal involvement: effect on plasma glutamate, aspartate and taurine.
Topics: Aspartic Acid; Atrophy; Basal Ganglia Diseases; Cerebellar Diseases; Cerebellum; Friedreich Ataxia; | 1983 |
Effects of some metabolic intermediates on AMP-deaminase activity in denervation atrophy.
Topics: AMP Deaminase; Animals; Aspartic Acid; Atrophy; Fumarates; Glutamates; Kinetics; Malates; Muscle Den | 1982 |
Brain proton magnetic resonance spectroscopy studies in recently abstinent alcoholics.
Topics: Adult; Aged; Alcoholism; Aspartic Acid; Atrophy; Brain; Cerebellum; Choline; Female; Humans; Magneti | 1995 |
Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy.
Topics: Adult; Aged; Aspartic Acid; Atrophy; Basal Ganglia; Brain Diseases; Choline; Creatine; Diagnosis, Di | 1995 |
Analysis of cerebral structural changes in systemic lupus erythematosus by proton MR spectroscopy.
Topics: Adolescent; Adult; Aspartic Acid; Atrophy; Brain; Choline; Creatine; Energy Metabolism; Female; Huma | 1994 |
Proton magnetic resonance spectroscopic imaging in patients with cerebellar degeneration.
Topics: Adult; Aged; Aspartic Acid; Atrophy; Cerebellar Diseases; Cerebellum; Choline; Creatine; Humans; Lac | 1996 |
Dietary glutamine supplementation prevents jejunal atrophy in weaned pigs.
Topics: Alanine; Animals; Aspartic Acid; Atrophy; Diet; Disease Models, Animal; Duodenum; Epithelium; Female | 1996 |
Temporal lobe epilepsy: bilateral hippocampal metabolite changes revealed at proton MR spectroscopic imaging.
Topics: Adult; Aspartic Acid; Atrophy; Choline; Creatine; Electroencephalography; Epilepsy, Temporal Lobe; F | 1997 |
Brain abnormalities demonstrated by magnetic resonance imaging in adult IDDM patients with and without a history of recurrent severe hypoglycemia.
Topics: Adult; Aspartic Acid; Atrophy; Blood Glucose; Brain; Cerebral Cortex; Choline; Cognition; Cohort Stu | 1997 |
Proton magnetic resonance spectroscopy in Parkinson's disease and atypical parkinsonian disorders.
Topics: Aged; Antiparkinson Agents; Aspartic Acid; Atrophy; Cerebral Cortex; Choline; Corpus Striatum; Creat | 1997 |
Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease. A proton MR spectroscopic imaging and MRI study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Atrophy; Female; Hippocampus; Humans; Mag | 1997 |
Decrease of N-acetylaspartate after ACTH therapy in patients with infantile spasms.
Topics: Adrenocorticotropic Hormone; Analysis of Variance; Anticonvulsants; Aspartic Acid; Atrophy; Brain; C | 1997 |
MR imaging and proton spectroscopy in 3-hydroxy-3-methylglutaryl coenzyme A lyase deficiency.
Topics: Amino Acid Metabolism, Inborn Errors; Aspartic Acid; Atrophy; Brain; Brain Diseases, Metabolic; Chil | 1998 |
Evidence of CNS impairment in HIV infection: clinical, neuropsychological, EEG, and MRI/MRS study.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS Dementia Complex; Aspartic Acid; Atrophy; Brain; CD4 | 1998 |
Proton magnetic resonance spectroscopy in acute, juvenile anorexia nervosa.
Topics: Adolescent; Anorexia Nervosa; Aspartic Acid; Atrophy; Brain; Brain Chemistry; Choline; Creatinine; F | 1998 |
Localized proton magnetic resonance spectroscopy of the cerebellum in detoxifying alcoholics.
Topics: Adult; Aged; Alcoholism; Aspartic Acid; Atrophy; Cerebellum; Choline; Female; Humans; Magnetic Reson | 1999 |
Brain proton magnetic resonance spectroscopy and brain atrophy in myotonic dystrophy.
Topics: Adolescent; Adult; Aspartic Acid; Atrophy; Case-Control Studies; Cerebral Cortex; Creatine; Female; | 1999 |
Proton magnetic resonance spectroscopy (1H MRS) in patients with sporadic cerebellar degeneration.
Topics: Adult; Aged; Aspartic Acid; Atrophy; Cerebellar Diseases; Cerebellum; Choline; Creatine; Disease Pro | 1999 |
MR image segmentation and tissue metabolite contrast in 1H spectroscopic imaging of normal and aging brain.
Topics: Adult; Age Factors; Aged; Aging; Aspartic Acid; Atrophy; Brain; Brain Chemistry; Choline; Creatine; | 1999 |
Prognostic value of proton magnetic resonance spectroscopic imaging for surgical outcome in patients with intractable temporal lobe epilepsy and bilateral hippocampal atrophy.
Topics: Adolescent; Adult; Aspartic Acid; Atrophy; Brain; Creatine; Dominance, Cerebral; Electroencephalogra | 2000 |
Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.
Topics: Animals; Animals, Genetically Modified; Aspartic Acid; Atrophy; Brain; Corpus Striatum; Creatine; Cr | 2000 |
Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.
Topics: Animals; Animals, Genetically Modified; Aspartic Acid; Atrophy; Brain; Corpus Striatum; Creatine; Cr | 2000 |
Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.
Topics: Animals; Animals, Genetically Modified; Aspartic Acid; Atrophy; Brain; Corpus Striatum; Creatine; Cr | 2000 |
Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.
Topics: Animals; Animals, Genetically Modified; Aspartic Acid; Atrophy; Brain; Corpus Striatum; Creatine; Cr | 2000 |
Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.
Topics: Animals; Animals, Genetically Modified; Aspartic Acid; Atrophy; Brain; Corpus Striatum; Creatine; Cr | 2000 |
Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.
Topics: Animals; Animals, Genetically Modified; Aspartic Acid; Atrophy; Brain; Corpus Striatum; Creatine; Cr | 2000 |
Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.
Topics: Animals; Animals, Genetically Modified; Aspartic Acid; Atrophy; Brain; Corpus Striatum; Creatine; Cr | 2000 |
Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.
Topics: Animals; Animals, Genetically Modified; Aspartic Acid; Atrophy; Brain; Corpus Striatum; Creatine; Cr | 2000 |
Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.
Topics: Animals; Animals, Genetically Modified; Aspartic Acid; Atrophy; Brain; Corpus Striatum; Creatine; Cr | 2000 |
Ultrasound measurement of brain atrophy in multiple sclerosis.
Topics: Aspartic Acid; Atrophy; Brain; Humans; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; | 2000 |
Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability.
Topics: Adult; Aspartic Acid; Atrophy; Axons; Brain; Chromatography, High Pressure Liquid; Creatine; Disabil | 2001 |
Human brain chemical shift imaging at age 60 to 90: analysis of the causes of the observed sex differences in brain metabolites.
Topics: Aged; Aged, 80 and over; Aspartic Acid; Atrophy; Brain; Brain Chemistry; Choline; Creatine; Female; | 2001 |
Reduced NAA in the thalamus and altered membrane and glial metabolism in schizophrenic patients detected by 1H-MRS and tissue segmentation.
Topics: Adult; Aspartic Acid; Atrophy; Choline; Creatine; Dominance, Cerebral; Energy Metabolism; Female; Hu | 2001 |
Decreased hippocampal N-acetylaspartate in the absence of atrophy in posttraumatic stress disorder.
Topics: Aspartic Acid; Atrophy; Brain; Case-Control Studies; Creatine; Hippocampus; Humans; Magnetic Resonan | 2001 |
Gerstmann syndrome in systemic lupus erythematosus: neuropsychological, neuroimaging and spectroscopic findings.
Topics: Adult; Agraphia; Apraxias; Aspartic Acid; Atrophy; Cerebral Infarction; Choline; Dominance, Cerebral | 2001 |
Selective reduction of N-acetylaspartate in medial temporal and parietal lobes in AD.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Aspartic Acid; Atrophy; Female; Hu | 2002 |
Abnormalities in neurotransmitter amino acids in dominantly inherited cerebellar disorders.
Topics: Amino Acids; Aspartic Acid; Atrophy; Brain Chemistry; Cerebellar Cortex; Cerebellar Diseases; Cerebe | 1978 |
Aspartate-taurine imbalance in dominantly inherited olivopontocerebellar atrophy.
Topics: Adult; Aspartic Acid; Atrophy; Brain; Brain Diseases; Cerebellar Cortex; Cerebellar Diseases; Female | 1977 |
Investigation of stroke in sickle cell disease by 1H nuclear magnetic resonance spectroscopy.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Aspartic Acid; Atrophy; Brain; Brain Ischemia; Cerebral Infa | 1992 |
1H and 31P magnetic resonance spectroscopy of the brain in degenerative cerebral disorders.
Topics: Adult; Aspartic Acid; Atrophy; Brain; Brain Diseases; Child; Creatine; Demyelinating Diseases; Human | 1992 |
Neurotransmitter receptors in olivopontocerebellar atrophy: an autoradiographic study.
Topics: Aged; Aspartic Acid; Atrophy; Autoradiography; Binding Sites; Cerebellum; gamma-Aminobutyric Acid; G | 1986 |
N-acetylaspartic aciduria in a child with a progressive cerebral atrophy.
Topics: Amino Acid Metabolism, Inborn Errors; Aspartic Acid; Atrophy; Brain; Child; Chromatography, Gas; Ery | 1986 |